Indirect costs: The consequence of production loss or increased costs of production

Medical Care

Volumn 34, Issue 12 SUPPL., 1996, Pages

  Koopmanschap, Marc A ^a   Rutten, Frans F H ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Indirect costs, pharmaceuticals, production loss, pharmaceuticals; Pharmaceutical product, production costs; Pharmacoeconomics

Indexed keywords

COST OF ILLNESS; ECONOMICS; HUMAN; NETHERLANDS; PHARMACOECONOMICS; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

COST OF ILLNESS; ECONOMICS, PHARMACEUTICAL; HUMANS; NETHERLANDS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); QUALITY OF LIFE;

EID: 0030340405     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Drummond MF. Cost-of-illness studies: A major headache? Pharmacoeconomics 1992;2:1.
2. Russell LB. Is prevention better than cure? Washington DC: The Brookings Institution, 1986.
3. Gerard K, Mooney G. QALY league tables: Handle with care. Health Economics 1993;2:59.
4. CCOHTA. Guidelines for economic evaluation of pharmaceuticals: Canada. Ottawa, Ontario: CCOHTA, 1994.
5. Henry DA. The Australian guidelines for subsidisation of pharmaceuticals. Pharmacoeconomics 1992;2:422.
6. Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: Including submissions involving economic analyses. Woden (ACT): Department of Health, Housing and Community Services, 1990.
7. van Roijen L, Essink-Bot ML, Koopmanschap MA, Michel B, Rutten FFH. A society's perspective on the burden of migraine. Pharmacoeconomics 1995;7:170.
8. Koopmanschap MA, Rutten FFH, Ineveld BM van, Roijen L van. The friction cost method for measuring indirect costs of disease. J Health Economics 1995;14:171.
9. Teulings CN, Koopmanschap MA. An econometric model of crowding out of lower education levels. European Economic Review 1989;33:1653.
10. CPB. Uncertainties on labour time reduction in the medium term [in Dutch]. The Hague: CPB, 1987. Working document 14.
11. CPB. FKSEC: A macro-econometric model for the Netherlands. Leiden/Antwerpen: Stenfert Kroese, 1992.
12. Koopmanschap MA, Rutten FFH. Indirect costs in economic studies: confronting the confusion. Pharmacoeconomics 1993;4:446.
13. Eelkman Rooda M, Barendregt J, Hattum J van, Hout BA van. Vaccination for hepatitis B: Costs and effects of eradication strategies [in Dutch]. Rotterdam: Institute for Medical Technology Assessment, Erasmus University Rotterdam, 1992.
14. Krahn M, Gafni A. Discounting in the economic evaluation of health care interventions. Med Care 1993;31:403.
15. Koning HJ de, Ineveld BM van, Oortmarssen GJ van, et al. Breast cancer screening and cost-effectiveness: Policy alternatives, quality of life considerations, and the possible impact of uncertain factors. International Journal of Cancer 1991;49:531.
16. Koopmanschap MA, Lubbe JThN, Oortmarssen GJ van, Agt HME van, Ballegooijen M van, Habbema DF. Economic aspects of cervical cancer screening. Soc Sci Med 1990;30:1081.
17. Hout BA van, Wielink G, Bonsel GJ, Rutten FFH. Effects of ACE inhibitors on heart failure in the Netherlands: A pharmacoeconomic model. Pharmacoeconomics 1993;26:387.
18. Jönsson B, Carlsson P. The effect of cimetidine on the cost of ulcer disease in Sweden. Soc Sci Med 1991;3:275.
19. Rutten-van Mölken MPMH, van Doorslaer EKA, Jansen MCC, Kerstjens HAM, Rutten FFH. Cost-effectiveness of inhaled corticosteroid and bronchodilator therapy in asthma and COPD. American Journal of Respiratory and Critical Care Medicine 1995;151:975.
20. Eelkman Rooda M, Barendregt J, van Hattum J, van Hout B. Vaccination for hepatitis B: Costs and effects of readication strategies [in Dutch]. Rotterdam: Institute for Medical Technology Assessment. Erasmus University Rotterdam, 1992.
21. Levin LA, Jönsson B. Cost-effectiveness of thrombolysis: A randomized study of intravenous rt-PA in suspected myocardial infarction. European Heart J 1992;13:2.
22. Cushner F, Friedman RJ. Economic impact of total hip arthroplasty. Southern Med J 1988;81:1379.